Following evaluation by an international panel of independent experts, the Project was scored as a high-quality project proposal in a highly competitive evaluation process. The Lentisoma project consists of an episomal non-integrative stable lentiviral vector that provides the lasting, stable and consistent expression of the transgene in dividing and non-dividing cells.

This is recognition of the work carried out by VIVEbiotech, a GMP Contract Development and Manufacturing Organization (CDMO) specialized in Lentiviral vectors.